AI Article Synopsis
- A study of 117 Hodgkin's disease patients in Sweden from 1985 to 1988 found that 27% tested positive for Epstein-Barr virus (EBV) in tumor cells.
- EBV-positivity varied across histopathological subgroups, with the highest in mixed cellularity (MC) tumors (38%) and the lowest in unclassified tumors (0%).
- Patients with EBV-positive tumors were generally older and had more severe symptoms, suggesting a trend toward poorer survival rates, though the differences were not statistically significant.
Article Abstract
All patients with Hodgkin's disease (HD) (n = 117) identified in the Uppsala/Orebro region of Sweden between 1985 and 1988 were examined for the presence of Epstein-Barr virus (EBV) in the Hodgkin and Reed-Sternberg (HRS) cells. EBV was detected with LMP-1 immunostaining and in situ hybridization for EBERs. Overall, 32 (27%) tumours were EBV-positive but there were significant differences in EBV-positivity between histopathological subgroups (p = 0.03). In MC, 8/21 (38%) were positive, in NS 20/67 (23%), LD 3/3, LP 1/5, and in unclassified 0/1. Patients with EBV-positive tumours were significantly older, mean 52 vs. 42 years (p = 0.02), and were likely to have significantly more B-symptoms or advanced stage disease. Patients with EBV-positive tumours tended to have a poorer survival rate (p = 0.11). The proportion of EBV-positive tumours, and especially the proportion of EBV-positive MC, was lower than previously reported. This could be explained by selection of patients from previous studies, or by differences in EBV-positivity in different geographical or ethnic populations of HD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/028418699431942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!